GLP-1 and Neuroscience: Reward, Addiction, and the Limits of Disease Modification GLP-1 receptor agonists are filed as metabolic drugs
On 21 May 2026, Lilly announced positive topline results from TRIUMPH-1 (not yet peer-reviewed), the pivotal Phase 3 obesity trial
GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic hormones your body produces naturally after eating
The strongly diabetogenic effect of GCs is caused by increased insulin resistance, driven primarily by increased hepatic gluconeogenesis, lipolysis, and elevated circulating free fatty acids (35)
The mix of textures also makes it feel more satisfying than a basic salad, while kale adds nutrients like vitamin C and potassium
Bismah Irfan, MD, sees the same handful of reconstitution errors repeatedly in her IVitality MD practice